EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)

被引：0
|
作者：
Taussig, David [1 ,2 ]
de Leeuw, David C. [3 ]
Jongen-Lavrencic, Mojca [4 ]
O'Nions, Jenny [5 ]
Koko, Thinzar [1 ,2 ]
Searle, Emma [6 ,7 ]
Fisher, Geoff [8 ]
Brook, Sue [8 ]
Arkenau, Hendrik-Tobias [8 ]
Yusuf, Ayan Aden [8 ]
Tan, Peter [9 ]
机构：
[1] Royal Marsden Hosp, London, England
[2] Inst Canc Res, London, England
[3] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[4] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[5] Univ Coll London Hosp NHS Fdn Trust, London, England
[6] Christie NHS Fdn Trust, Manchester, Lancs, England
[7] Univ Manchester, Manchester, England
[8] Ellipses Pharm, London, England
[9] Royal Perth Hosp, Perth, Australia
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-210105
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1500 / 1501
页数：2
相关论文
共 50 条
  • [1] EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Results from an Ongoing Phase I/IIa Dose-Finding/Dose Optimization Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Taussig, David
    de Leeuw, David C.
    Jongen-Lavrencic, Mojca
    O'Nions, Jenny
    Koko, Thinzar
    Searle, Emma
    Arkenau, Hendrik-Tobias
    Brook, Sue
    Burmester, Charlotte
    Fisher, Geoff
    Stoddart, Katie
    Tan, Peter
    BLOOD, 2023, 142
  • [2] EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Preliminary Results of an Ongoing Phase I/IIa First in Human Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Taussig, David
    O'Nions, Jenny
    Jongen-Lavrencic, Mojca
    Janssen, Jeroen J.
    de Leeuw, David C.
    Tan, Peter T.
    Brook, Sue
    Stoddart, Katie
    Arkenau, Hendrik-Tobias
    Fisher, Geoff
    BLOOD, 2022, 140 : 6222 - 6223
  • [3] Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
    Daver, Naval G.
    Assi, Rita
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Ravandi, Farhad
    Konopleva, Marina Y.
    Kadia, Tapan M.
    Borthakur, Gautam
    Jabbour, Elias J.
    DiNardo, Courtney D.
    Velasquez, Michelle
    Kelly, Mary
    Ning, Jing
    Gonzalez, Graciela M. Nogueras
    Pierce, Sherry A.
    Gombos, Dan
    Estrov, Zeev E.
    Kornblau, Steven M.
    Zhang, Weiguo
    Andreeff, Michael
    BLOOD, 2018, 132
  • [4] Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
    Walker, Alison R.
    Bergua Burgues, Juan Miguel
    Montesinos, Pau
    Bixby, Dale
    Guastad Daver, Naval
    Konopleva, Marina
    Patrick Anthony, Stephen
    Tan, Fenlai
    Chen, Yi
    Chen, Yu
    Shen, Yue
    William Burke, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia
    Yee, Karen W. L.
    Chen, Hsiao-Wei T.
    Hedley, David W.
    Chow, Sue
    Brandwein, Joseph
    Schuh, Andre C.
    Schimmer, Aaron D.
    Gupta, Vikas
    Sanfelice, Deborah
    Johnson, Tara
    Le, Lisa W.
    Arnott, Jamie
    Bray, Mark R.
    Sidor, Carolyn
    Minden, Mark D.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (05) : 614 - 624
  • [6] A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia
    Karen W. L. Yee
    Hsiao-Wei T. Chen
    David W. Hedley
    Sue Chow
    Joseph Brandwein
    Andre C. Schuh
    Aaron D. Schimmer
    Vikas Gupta
    Deborah Sanfelice
    Tara Johnson
    Lisa W. Le
    Jamie Arnott
    Mark R. Bray
    Carolyn Sidor
    Mark D. Minden
    Investigational New Drugs, 2016, 34 : 614 - 624
  • [7] A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
    Daver, Naval
    Assi, Rita
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Jabbour, Elias
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Ning, Jing
    Nogueras-Gonzalez, Graciela
    Pierce, Sherry
    Gombos, Dan
    Komblau, Steven
    Konopleva, Marina
    Kelly, Mary
    Borthakur, Gautam
    Zhang, Weiguo
    Cortes, Jorge
    Kantarjian, Hagop
    Andreeffl, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S7 - S8
  • [8] a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
    Daver, Naval
    Assi, Rita
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Borthakur, Gautam
    Jabbour, Elias J.
    DiNardo, Courtney D.
    Kadia, Tapan
    Ning, Jing
    Gonzalez, Graciela Nogueras
    Pierce, Sherry
    Kelly, Mary
    Zhang, Weiguo
    Gombos, Dan
    Kornblau, Steven
    Konopleva, Marina
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Andreeff, Michael
    BLOOD, 2017, 130
  • [9] Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
    Pemmaraju, Naveen
    Bhalla, Kapil N.
    Daver, Naval
    Wilson, Nathaniel R.
    Fiskus, Warren C.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Burger, Jan A.
    Short, Nicholas J.
    Alvarado, Yesid
    Jain, Nitin
    Masarova, Lucia
    Verstovsek, Srdan
    Issa, Ghayas C.
    Qiao, Wei
    Khoury, Joseph D.
    Pierce, Sherry A.
    Miller, Darla
    Konopleva, Marina
    Kantarjian, Hagop
    Borthakur, Gautam
    BLOOD, 2021, 138
  • [10] A Phase I Study of FLX925, a Dual FLT3 and CDK4/6 Inhibitor in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Daver, Naval
    Pollyea, Daniel A.
    Rizzieri, David A.
    Palmer, Jeanne
    Rampal, Raajit K.
    Dinner, Shira
    Bixby, Dale L.
    Percival, Mary-Elizabeth M.
    Kovacsovics, Tibor
    Begna, Kebede H.
    Perl, Alexander E.
    Konopleva, Marina
    Seitz, Lisa
    McKinnell, Jenny
    Johnson, Daniel T.
    Ho, William
    Cortes, Jorge E.
    BLOOD, 2017, 130
12345